Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Imperial College London.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00180778
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?


Condition Intervention Phase
Antiphospholipid Syndrome
Drug: Low dose steroids
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Successful pregnancy outcome

Estimated Enrollment: 90
Study Start Date: October 2005
Detailed Description:

Over the last decade, the APS has emerged as most important treatable cause of recurrent miscarriages. The pathogenesis of fetal loss in this condition is still remains obscure. Despite the success of aspirin + heparin treatment, some pregnant women with APS repeatedly miscarry even on treatment. The trial is designed to determine if addition of steroids has an success in these women. This is in view of recent in vitro data from our unit reporting that there is an increase decidual cytokine response in APS positive women.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

History of 3 or more consecutive miscarriages and positive antiphospholipid antibodies on at least two occasions more than 6 weeks apart before becoming pregnant and an unsuccessful pregnancy with aspirin + heparin with a karyotype of miscarriage either unavailable or normal (46XX/ 46XY).

Exclusion Criteria:

Abnormal karyotype of women or partner, previous thromboembolism, SLE, diabetes mellitus, hypertension, sensitivity to aspirin, heparin and prednisolone, multiple pregnancy.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180778

Contacts
Contact: Lesley Regan, FRCOG 02078861050 l.regan@imperial.ac.uk

Locations
United Kingdom
St. Mary's Hospital Not yet recruiting
London, United Kingdom, W2 1NY
Contact: Lesley Regan, FRCOG    02078861050    l.regan@imperial.ac.uk   
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Raj Rai, MRCOG Imperial College London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00180778     History of Changes
Other Study ID Numbers: 05/Q0403/155, 2005-004182-42
Study First Received: September 13, 2005
Last Updated: September 13, 2005
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Syndrome
Antiphospholipid Syndrome
Disease
Pathologic Processes
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on September 18, 2014